Recent advances in the management of adult myositis

Bibliography

• MEDSGER JR TA, ODDIS CV: Classification and diagnostic criteria for polymyositis and dermatomyositis. Rheumatol (1995) 22:581–585
   Web of Science ®Google Scholar
• AMATO AA, BAROHN RJ: Idiopathic inflammatory myopathies. Neurologic Clinics (1997) 15:616–648.
   Google Scholar
• ODDIS CV: Idiopathic inflammatory diseases of muscle. In: Diseases of Skeletal Muscle. Wortmann RL (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA. (2000):45–85.
   Google Scholar
• GHATE J, KATSAMBAS A, AUGERINOU G, JORIZZO JL: A therapeutic update on dermatomyositis/ polymyositis. Internat. j Dermatol. (2000) 39:81–87.
   PubMed Web of Science ®Google Scholar
• ODDIS CV: Current approach to the treatment of polymyositis and dermatomyositis. Curr. Opin. Rheumatol (2000) 12:492-497. esA succinct review of newer aspects in the treatment of polymyositis and dermatomyositis.
   Google Scholar
• LUNDBERG I, CHUNG Y-L: Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology (2000) 39:7–17.
   PubMed Web of Science ®Google Scholar
• ▪A comprehensive up-to-date review of the investigations and treatment of inflammatory myositis.
   Google Scholar
• BUNCH TW: Prednisone and azathioprine for polymyositis. Arthritis Rheum. (1981) 24:45–48.
   PubMed Web of Science ®Google Scholar
• MILLER FW, LEITMAN SF, CRONIN ME et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl. j Med. (1992) 326:130–134.
   Google Scholar
• DALAKAS MC, ILLA I, DAMBROSIA JM et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl. Med. (1993) 329:1993–2000.
   PubMed Web of Science ®Google Scholar
• DALAKAS MC, DAMBROSIA J, SEKUL E et al.: Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology (1997) 48:712–716.
   PubMed Web of Science ®Google Scholar
• VILLALBA L, HICKS JE, ADAMS EM et al.: Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. (1998) 41:392-399. seCombination therapy with oral MTX andAZA was more effective than intravenous methotrexate and folinic acid rescue in a randomised crossover study of 30 patients with refractory myositis.
   Google Scholar
• VENCOVSKY J, JARSOVA K, MACHACEK S etal.: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scam/. Rheumatol. (2000) 29:95–102.
   Google Scholar
• •An open-label randomised study comparing MTX to cyclosporine in 36 corticosteroid-treated patients with polymyositis/ dermatomyositis showing both drugs to be equally efficacious.
   Google Scholar
• MESSNER RP: Pathogenesis of idiopathic inflammatory myopathies. In: Diseases of Muscle. Wortmann RL (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA. (2000):111–127.
   Google Scholar
• PLOTZ PH, RIDER LG, TARGOFF IN, RABEU N, O'HANLON TI MILLER TW: Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann. Intern. Med. (1995) 122:715–724.
   PubMed Web of Science ®Google Scholar
• ASKANAS V, ENGEL WK: Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Cun: Opin. Rheum. (1998) 10:530–549.
   PubMedGoogle Scholar
• LUNDBERG I, ULFGREN A-K, NYBERG P et al: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. (1997) 40:865–874.
   PubMed Web of Science ®Google Scholar
• LUNDBERG IE, NYBERG P: New developments in the role of cytokines and chemokines in inflammatory myopathies. Cun: Opin. Rheumatol (1998) 10:521–529.
   PubMedGoogle Scholar
• NYBERG P, WIKMAN A-L, NENNESMO I, LUNDBERG I: Increased expression of interleukin 1 a and MHC class I in muscle tissue of patients with chronic inactive polymyositis and dermatomyositis. I Rheumatol. (2000) 27:940–948.
   Web of Science ®Google Scholar
• CALABRESE LH, CHOU SM: Inclusion body myositis. Rheum. Dis. Clio. North Am. (1994) 20:955–972.
   PubMed Web of Science ®Google Scholar
• WORTMANN RL: Idiopathic inflammatory myopathies. In: Treatment of the Rheumatic Diseases. Weisman MH, Weinblatt ME (Ed.) W.B. Saunders Co., Philadelphia, USA (1995):201–216.
   Google Scholar
• KAGEN LJ, ARAM S: Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum. (1987) 30:213–217.
   PubMed Web of Science ®Google Scholar
• ADAMS EM, PLOTZ PH: The treatment of myositis: How to approach resistant disease. Rheum. Dis. CM]. N Am. (1995) 21:179–202.
   PubMed Web of Science ®Google Scholar
• NZEUSSEU A, BRION F, LEFEBVRE C, et al: Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Exper. Rheumatol. (1999) 17:441–446.
   Web of Science ®Google Scholar
• •A retrospective analysis of 25 patients with non-cancer-associated myositis treated with cytotoxic drugs, and either high-dose or low-dose corticosteroid therapy, showing that those receiving the lower-dose regimen achieved a similar functional outcome and fewer side-effects compared to patients treated with higher doses of corticosteroids.
   Google Scholar
• JOFFE MM, LOVE LA, LEFF RL et al: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am. J. Med. (1993) 94:379–387.
   PubMed Web of Science ®Google Scholar
• CRONIN ME, MILLER FW, HICKS JE, DALAKAS M, PLOTZ PH: The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. Rheumatol. (1989) 16:1225–1228.
   Web of Science ®Google Scholar
• HUANG J-L: Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone therapy. OM. Exp. Rheumatol. (1999) 17:621–624.
   PubMed Web of Science ®Google Scholar
• AL-MAYOUF S, AL-MAZYED A, BAHABRI S: Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Chia. Rheumatol. (2000) 19:138–141.
   Web of Science ®Google Scholar
• •A retrospective review showing the effectiveness of early treatment of severe, complicated juvenile dermatomyositis with both intravenous pulse methylprednisolone and oral methotrexate.
   Google Scholar
• BOLOSIU HD, MAN L, REDNIC S: The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. In: RheumaDerm, Mallia & Uitto (Ed.) New York, USA (1999):349–357.
   Google Scholar
• YOCUM DE: Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum. Dis. Clinics North Am (1996) 22:133–154.
   PubMed Web of Science ®Google Scholar
• ZELLER V, COHEN P, PRIEUR A-M, GUILLEVIN L: Cyclosporine A therapy in refractory juvenile dermatomyositis. Experience and long-term follow-up of 6 cases. J. Rheumatol (1996) 23:1424–1427.
   Google Scholar
• QUSHMAQ KA, CHALMERS A, ESDAILE JM: Cyclosporine A in the treatment of refractory adult polymyositis/ dermatomyositis : population based experience in 6 patients and literature review. J. Rheumatol. (2000) 27:2855–2859.
   PubMed Web of Science ®Google Scholar
• •A retrospective analysis of cyclosporin treatment of six patients with refractory polymyositis/dermatomyositis, and a comprehensive literature review.
   Google Scholar
• GRAU JM, HERRERO C, CASADEMONT J etal.: Cyclosporine A as first choice therapy for dermatomyositis (Letter). J. Rheumatol (1994) 21:381–382.
   Google Scholar
• ODDIS CV, SCIURBA FC, ELMAGD KA, STARZL TE: Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet (1999) 353:1762–1763.
   PubMed Web of Science ®Google Scholar
• •An open-label pilot study showing tacrolimus to be effective in eight patients with refractory polymyositis, including five patients with interstitial pulmonary disease and anti-Jo-1 antibodies.
   Google Scholar
• ADAMS EM, PUCINO E YARBORO C et al.: A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol (1999) 26: 352–360.
   Google Scholar
• •A preliminary investigation demonstrating the effectiveness of fludarabine in a subset of patients with severe myositis refractory to both corticosteroids and other immunosuppressive drugs.
   Google Scholar
• KLASSEN LW, CALABRESE LH, LAXER RIVI: Intravenous immunoglobulin in rheumatic disease. Rheum. Dis. Clinics N Am. (1996) 22:155–173.
   PubMed Web of Science ®Google Scholar
• YU Z, LENNON VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N. Engl. J Med. (1999) 340:227–228.
   PubMed Web of Science ®Google Scholar
• •An update review shedding light on the mechanism of action of intravenous immunoglobulin in the treatment of myositis and other antibody-mediated autoimmune diseases. The article discusses the role of saturation of IgG transport receptor, FcRn, resulting in accelerated rate of catabolism of both exogenous IgG (IVIC.) and endogenous pathogenetic IgG autoantibodies.
   Google Scholar
• CHERIN P, PIETTE JC, WECHSLER B et al.: Intravenous gamma globulin as first-line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol (1994) 21:1092–1097.
   PubMed Web of Science ®Google Scholar
• GOTTEFRIED I, SEEBER A, ANEGG B et al.: High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur. j Dermatol (2000) 10:29–35.
   PubMed Web of Science ®Google Scholar
• •WIG is particularly effective in a subset of patients with dermatomyositis with severe skin disease, moderate muscle involvement and no anti-Jo-1 antibodies or concomitant malignancy. Serum soluble IL-2 receptor levels are useful predictors of an IVIG-induced treatment response.
   Google Scholar
• HENGSTMAN F, HOOGEN FVD, ENGELEN BV, BARRERA P et al: Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheum. (Abstract) (2000) 43 (Suppl.) :S193.
   Google Scholar
• •A promising pilot trial of infliximab, a TNF-a blocking drug, in the treatment of two patients with refractory myositis.
   Google Scholar
• SAADEH CK: Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum. (Abstract) (2000) 43:(Suppl.)S193.
   Google Scholar
• •A preliminary study demonstrating the effectiveness of etanercept, a soluble TNF receptor antagonist, in the treatment of four patients with corticosteroid- and cytotoxic-resistant myositis.
   Google Scholar
• DRUG REPORT: 5G1.1 Investigational drugs database, Alexion Pharmaceuticals, Inc. (2000).
   Google Scholar
• •A study in progress evaluating the efficacy and safety profile of 5G1.1, an anti-05 complement monoclonal antibody (anti-complement cascade drug), in the treatment of dermatomyositis.
   Google Scholar
• ESCALANTE A, MILLER L, BEARDMORE TD: Resistive exercises in the rehabilitation of polymyositis/ dermatomyositis. j Rheumatol (1993) 20:1340–1344.
   PubMed Web of Science ®Google Scholar
• HICKS JE: Role of rehabilitation in the management of myopathies. Curr. Opirt. Rheumatol (1998):548–555.
   Google Scholar
• ALEXANDERSON H, STENSTROM CH, LUNDBERG I: Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (1999) 38:608–611.
   PubMed Web of Science ®Google Scholar
• LEFF RL, MILLER FW, HICKS J, FRASER DD, PLOTZ PH: The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (1993) 72:225–235.
   PubMed Web of Science ®Google Scholar
• BAROHN RJ, AMATO AA, SAHENK Z et al.: Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology (1995) 45:1302–1304.
   PubMed Web of Science ®Google Scholar
• AMMO AA, BAROHN RJ, JACKSON CE et al.: Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology (1994) 44:1516–1518.
   PubMed Web of Science ®Google Scholar
• SPECTOR SA, LEMMER JT, KOFFMANBM et al: Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve (1997) 20:1242–1248.
   PubMed Web of Science ®Google Scholar
• KELLY JJ, MADOC-JONES H, ADELMAN LS et al: Response to total boy irradiation in dermatomyositis. Muscle & Nerve (1988) 11:120–123.
   PubMed Web of Science ®Google Scholar
• CUMMING WJK: Thymectomy in refractory dermatomyositis. Muscle Nerve (Letter) (1989) 12:424.
   Web of Science ®Google Scholar
• SINOWAY PA, CALLEN JP: Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. (1993) 36:319–324.
   PubMed Web of Science ®Google Scholar
• ROVENSKY J, ZITMAN D, LEDUC J,TAUCHMANNOVA H: Effect of levamisole treatment in polymyositis patients. j Rheumatol. (Letter) (1982) 9:158–159.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA H, HARIGAI M, HARA M et al.: KL-6 as a novel serum marker for interstitial pneumonia associated with collagen disease. I Rheumatol (2000) 27:1164–1170.
   Web of Science ®Google Scholar
• •A recent study suggesting that measurement of serum levels of KL-6, a mucirtous glycoprotein expressed on Type II pneumocytes, may be useful in the diagnosis and monitoring of myositis-associated interstitial lung disease.
   Google Scholar
• SCHNABEL A, REUTER M, GROSS WL: Intravenous pulse cyclophosphamide in the treatment of lung disease due to collagen vascular diseases. Arthritis Rheum. (1998) 41:1215–1220.
   PubMed Web of Science ®Google Scholar
• YOSHIDA T, KOGA H, SAITOH F et al:Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Internal Medicine (1999) 38:733–738.
   PubMed Web of Science ®Google Scholar
• NAWATA Y, KURASAWA K, TAKABAYASHI K et al.: Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. Rheumatol (1999) 26:1527–1533.
   Web of Science ®Google Scholar
• •A retrospective study demonstrating a beneficial effect of low-dose cyclosporine in 5 patients with myositis and corticosteroid-resistant interstitial pulmonary disease.
   Google Scholar
• MAEDA K, KIMURA R, KOMUTA K, IGARASHI T: Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scant/. Rheumatol. (1997) 26:24–29.
   Web of Science ®Google Scholar
• PEAKE MF, PERKINS P, ELSTON DM et al.: Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Culls (1998) 62:89–93.
   Google Scholar
• SADAYAMA T, MIYAGOWA S, SHIRAI T: low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. j Dermatol (1999) 26:457–459.
   PubMedGoogle Scholar
• •Low-dose intravenous immunoglobulin (0.1 g/kg/day for 5 days/week for two weeks) was effective in the treatment of corticosteroid-resistant skin lesions of a patient with dermatomyositis and minimal muscle disease.
   Google Scholar
• GELBER AC, NOUSARI HC, WIGLEY FM: Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. Rheumatol. (2000) 27:1542–1545.
   Web of Science ®Google Scholar
• •A preliminary study showing a beneficial effect of mycophenolate mofetil in 4 patients with DM and refractory cutaneous lesions.
   Google Scholar
• FAM AG: Basic calcium phosphate (calcium apatite) crystal disposition diseases. In: Gout, hyperuricemia, and other crystal-associated arthropathies. Smythe CT, Holers WM (Eds.) Marcel Dekker, Inc. New York, USA (1999):333–358.
   Google Scholar
• MARIE I, HACHULLA E, LEVESQUE H et al.: Intravenous immunoglobulins as treatment of life-threatening esophageal involvement in polymyositis and dermatomyositis. I Rheumatol. (1999) 26:2706–2709
   Web of Science ®Google Scholar